Tiny Health and Rupa Health Team Up to Transform Preventative Care
26 juin 2024 08h30 HE
|
Tiny Health
Partnership expands access to comprehensive at-home microbiome testing, aiming to address health issues at the root cause
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
30 mai 2024 18h01 HE
|
Novartis Pharma AG
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
16 mai 2024 17h29 HE
|
Foundation for Sarcoidosis Research
Foundation for Sarcoidosis Research Launches the Coalition for Clinical Trial Equity to Address Barriers Faced by Black Patients
Foundation for Sarcoidosis Research Launches Say Sarcoidosis Campaign to Shed Light on the 1.2 Million People Impacted by Sarcoidosis for April’s Awareness Month
01 avr. 2024 07h41 HE
|
Foundation for Sarcoidosis Research
FSR Launches Say Sarcoidosis campaign for April's Awareness Month
26 Patient Volunteer Leaders Attend the Foundation for Sarcoidosis Research Global Sarcoidosis Clinic Alliance Volunteer Patient Leadership Advanced Training Conference held at Cleveland Clinic
27 mars 2024 06h41 HE
|
Foundation for Sarcoidosis Research
26 Patient Volunteer Leaders joined the Foundation for Sarcoidosis Research at Cleveland Clinic for the Leadership Advanced Training Conference
Tiny Health, Pioneer of the First At-Home Baby Gut Microbiome Test, Aims to Address the Pediatric Chronic Conditions Crisis
05 mars 2024 09h00 HE
|
Tiny Health
AUSTIN, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Tiny Health, the first at-home gut microbiome test developed for babies, today announced a $8.5 million Series A round led by Spero Ventures,...
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
04 mars 2024 01h15 HE
|
Novartis Pharma AG
The SMART study supplements a growing body of evidence on the use of Zolgensma in a patient population older and heavier (1.5 – 9.1 years of age) than the children treated in previous clinical studies...
Tricha Shivas Promoted to Chief of Staff and Strategy at Foundation for Sarcoidosis Research
15 févr. 2024 06h23 HE
|
Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) proudly announces the promotion of Tricha Shivas to Chief of Staff and Strategy.
The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis
18 déc. 2023 15h41 HE
|
Foundation for Sarcoidosis Research
The Foundation for Sarcoidosis Research (FSR) awards $100,000 in support of cardiac sarcoidosis.
Novartis data show potential of remibrutinib as an oral treatment for chronic spontaneous urticaria providing significant symptom improvement as early as Week 2
09 nov. 2023 11h00 HE
|
Novartis Pharma AG
In pivotal Phase III trials, remibrutinib – a highly selective, oral Bruton’s tyrosine kinase inhibitor – demonstrated clinically meaningful and statistically significant reduction in urticaria...